Bedford, Massachusetts — Otto Bock HealthCare GmbH, a global leader in prosthetics and orthotics, announced the acquisition of BionX Medical (BionX), a US-based portfolio company of Gilde Healthcare. BionX’s flagship product is emPOWER, the world’s only active prosthetic foot that adapts to changing surfaces and walking speeds. Ottobock has been distributing the emPOWER prosthetic foot exclusively in the markets of the DACH-Region, Scandinavia and the UK since last year. With the acquisition of BionX, the German company now also takes over the global marketing. Financial terms of the transaction were not disclosed.

BionX was founded in 2007 by Dr. Hugh Herr, Director of the Biomechatronics Group at the Massachusetts Institute of Technology (MIT).

About Gilde Healthcare

Gilde Healthcare is a specialized trans-Atlantic healthcare investor managing two business lines: a venture & growth capital fund and a lower mid-market buy-out fund. Gilde Healthcare’s venture & growth capital fund invests in medtech, diagnostics, digital health and therapeutics. The portfolio companies are based in Europe and North America. Gilde Healthcare’s lower mid-market buy-out fund invests in profitable European healthcare services companies with a focus on the Netherlands, Belgium and Germany. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market.
Since 2001 Gilde Healthcare has raised €800 million ($900 million) for its specialized funds. For more details see www.gildehealthcare.com